We Offer Worldwide Shipping
Login Wishlist

Wogonoside

$178

  • Brand : BIOFRON

  • Catalogue Number : BF-W3003

  • Specification : 95%

  • CAS number : 51059-44-0

  • Formula : C22H20O11

  • Molecular Weight : 460.39

  • PUBCHEM ID : 3084961

  • Volume : 100mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BF-W3003

Analysis Method

HPLC,NMR,MS

Specification

95%

Storage

2-8°C

Molecular Weight

460.39

Appearance

White crystalline powder

Botanical Source

Scutellaria baicalensis,Adenophora tetraphylla

Structure Type

Flavonoids

Category

Standards;Natural Pytochemical;API

SMILES

COC1=C(C=C(C2=C1OC(=CC2=O)C3=CC=CC=C3)O)OC4C(C(C(C(O4)C(=O)O)O)O)O

Synonyms

5-Hydroxy-8-methoxy-4-oxo-2-phenyl-4H-chromen-7-yl β-D-glucopyranosiduronic acid/Oroxindin/Wogonin 7-β-D-glucuronide/wogonin 7-O-glucuronoside/wogonin 7-O-β-D-glucuronide/2-C-(5-Hydroxy-8-methoxy-4-oxo-2-phenyl-4H-chromen-7-yl)-D-glucuronic acid/4H-1-Benzopyran-4-one, 7-(β-D-glucopyranuronosyloxy)-5-hydroxy-8-methoxy-2-phenyl-/Wogonin-7-O-|A-D-glucuronide/Wogonoside/Wogonin 7-O-glucuronide/Glychionide B/D-Glucuronic acid, 2-C-(5-hydroxy-8-methoxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl)-/5,7-dihydroxy-8-methoxyflavone 7-O-β-D-glucuronide

IUPAC Name

(2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(5-hydroxy-8-methoxy-4-oxo-2-phenylchromen-7-yl)oxyoxane-2-carboxylic acid

Density

1.6±0.1 g/cm3

Solubility

DMF

Flash Point

304.0±27.8 °C

Boiling Point

869.0±65.0 °C at 760 mmHg

Melting Point

226-227ºC

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

2938900000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:51059-44-0) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

PMID

29990847

Abstract

Non-small cell lung cancer (NSCLC) is one of the most prevailing malignancies worldwide. It has been previously shown that wogonoside exerts anti-tumor activities in various kinds of human cancers. But its role in NSCLC remains elusive. In the present study, we determined the anti-tumor effect of wogonoside in human NSCLC A549 cells. We found that wogonoside effectively inhibits A549 cell viability through inducing cell cycle arrest and apoptosis. Moreover, administration of wogonoside by intraperitoneal injection inhibits the growth of A549 cell xenografts in athymic nude mice. Additionally, mitochondrial membrane potential was disrupted and cytochrome c was released to cytosol in the wogonoside-treated A549 cells. Finally, we found that AMPK/mTOR signaling might be implicated in the anti-NSCLC efficacy of wogonoside. Therefore, we may assume that wogonoside may be considered as a potential therapeutic agent for the treatment of NSCLC.

Copyright © 2018 Elsevier Masson SAS. All rights reserved.

KEYWORDS

AMPK/mTOR signaling; Apoptosis; Mitochondria; Non-small cell lung cancer; Viability; Wogonoside

Title

Wogonoside induces apoptosis in human non-small cell lung cancer A549 cells by promoting mitochondria dysfunction.

Author

Luo M1, Mo J1, Yu Q2, Zhou S2, Ning R2, Zhang Y1, Su C2, Wang H1, Cui J3.

Publish date

2018 Oct

PMID

25677765

Abstract

Previous studies have demonstrated that wogonoside, the glucuronide metabolite of wogonin, has anti-inflammatory, anti-angiogenic and anticancer effects. However, the anti-inflammatory mechanism of wogonoside has not been fully elucidated. Recently, NLRP3 inflammasome has been reported to be correlated with inflammatory bowel disease for its ability to induce IL-1β release. Nevertheless, there are few drug candidates targeting NLRP3 inflammasome for this disease. In this study, we investigated the anti-inflammatory effect of wogonoside in dextran sulfate sodium (DSS)-induced murine colitis and further revealed the underlying mechanisms by targeting NF-κB and NLRP3 inflammasome. Wogonoside treatment dose-dependently attenuated DSS-induced body weight loss and colon length shortening. Moreover, wogonoside prevented DSS-induced colonic pathological damage, remarkably inhibited inflammatory cells infiltration and significantly decreased myeloperoxidase (MPO) and inducible nitric oxide synthase (iNOS) activities. The production of pro-inflammatory mediators in serum and colon was also significantly reduced by wogonoside. The underlying mechanisms for the protective effect of wogonoside in DSS-induced colitis may be attributed to its inhibition on NF-κB and NLRP3 inflammasome activation in colons. Furthermore, wogonoside markedly decreased production of IL-1β, TNF-α and IL-6 and suppressed mRNA expression of pro-IL-1β and NLRP3 in phorbol myristate acetate (PMA)-differentiated monocytic THP-1 cells via inhibiting the activation of NF-κB and NLRP3 inflammasome. In conclusion, our study demonstrated that wogonoside may exert its anti-inflammatory effect via dual inhibition of NF-κB and NLRP3 inflammasome, suggesting that wogonoside might be a potential effective drug for inflammatory bowel diseases.

Copyright © 2015 Elsevier Inc. All rights reserved.

KEYWORDS

5-ASA (PubChem CID: 4075); CMC (PubChem CID: 6328154); Colitis; DAPI (PubChem CID: 2954); DMSO (PubChem CID: 679); IL-1β; LPS (PubChem CID: 53481793); NF-κB; NLRP3 inflammasome; PMA (PubChem CID: 27924); Wogonoside; Wogonoside (PubChem CID: 29927693)

Title

Wogonoside protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-κB and NLRP3 inflammasome activation.

Author

Sun Y1, Zhao Y1, Yao J1, Zhao L1, Wu Z1, Wang Y1, Pan D1, Miao H1, Guo Q2, Lu N1.

Publish date

2015 Mar 15

PMID

31480051

Abstract

BACKGROUND:
Wogonoside, an effective component of Scutellaria baicalensis extract, has recently become a hot topic for its newly discovered anticancer efficacy, but the underlying pharmacological mechanism is still unclear. In this study, we tested the inhibitory effects of wogonoside in human prostate cancer PC3 cells in vitro and vivo.

METHODS:
The effects of wogonoside on cell viability, cycle progression, invasion, migration, and apoptosis were assessed in vitro. The levels of proteins in related signaling pathways were detected by western blotting assay. Finally, nude mouse tumorigenicity assay was conducted to detect the anticancer effect of wogonoside in vivo.

RESULTS:
Wogonoside inhibited cell viability, invasive and migratory ability in a time- and dose-dependent manner. Flow cytometry indicated that wogonoside could induce cell apoptosis and S phase cell-cycle arrest. Mechanically, wogonoside suppressed the Wnt/β-catenin signaling pathway, and the level of p-glycogen synthase kinase-3β (GSK-3β; Ser9) was inhibited by wogonoside. The epithelial-mesenchymal transition (EMT) process was also reversed in PC3 cell line after wogonoside treatment. In vivo experiments showed that wogonoside inhibited tumor growth in xenograft mouse models.

CONCLUSION:
These findings revealed that wogonoside could suppress Wnt/β-catenin pathway and reversing the EMT process in PC3 cells. GSK-3β acts as a tumor suppressor in prostate cancer. Wogonoside may serve as an effective agent for treating prostate cancer.

© 2019 S. Karger AG, Basel.

KEYWORDS

Epithelial-mesenchymal transition; Prostate cancer; Wogonoside; β-Catenin

Title

Wogonoside Inhibits Prostate Cancer Cell Growth and Metastasis via Regulating Wnt/β-Catenin Pathway and Epithelial-Mesenchymal Transition.

Author

Wei C1, Jing J2, Zhang Y2, Fang L3.

Publish date

2019


Description :

Wogonoside, a flavonoid glycoside isolated from Huangqin, possesses anti-inflammatory effects. Wogonoside induces autophagy in breast cancer cells by regulating MAPK-mTOR pathway[1][2].